Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 4Other solid neoplasm 2Dermatologic 2Thoracic 1Gastrointestinal 1

Conditions

Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

pembrolizumab 26Pemetrexed 26Cisplatin 25Nivolumab 22Carboplatin 16Paclitaxel 14Gemcitabine 12Ipilimumab 11tislelizumab 8durvalumab 8Ramucirumab 8Docetaxel 8talazoparib 7Fluorouracil 7Radiotherapy 6Capecitabine 6tremelimumab 5cobimetinib 5atezolizumab 5adavosertib 5Radiosurgery 5Cyclophosphamide 5Bevacizumab 5olaparib 4avelumab 4Temozolomide 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × mogamulizumab × Other solid neoplasm × Clear all
NCT02281409 2021-04-23

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
17 enrolled 13 charts
Other solid neoplasm

Advanced Solid Tumors

NCT02444793 2019-02-27

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
24 enrolled 34 charts
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡